Boston Scientific Corporation

Boston Scientific Corporation is an American medical device manufacturer whose products are used in minimally invasive interventional procedures across cardiology, peripheral vascular intervention, endoscopy, urology and neuromodulation. It generated $20.07 billion of net sales in fiscal 2025 across two reportable segments, MedSurg and Cardiovascular.

For three years this was among the most reliable growth stories in large-cap medical technology. Organic revenue grew 15.8% in 2025, carried by the FARAPULSE pulsed-field ablation (PFA) franchise and the WATCHMAN left-atrial-appendage device; adjusted operating margin reached 28.0%; adjusted diluted earnings per share rose 22% to $3.06. Management entered 2026 guiding to 10% to 11% organic growth and adjusted EPS of $3.43 to $3.49. Then the narrative broke in public. In April the company cut the revenue guide to 6.5% to 8% and EPS to $3.34 to $3.41; in late July it cut again, to 5% to 6% organic and $3.28 to $3.32, and said 2027 would bring "limited EPS growth." The shares closed at $48.43 on 3 August 2026, less than half the 52-week closing high of $108.14 they touched in September 2025.

The file turns on one question: whether electrophysiology and WATCHMAN — together a little over a quarter of revenue — have hit a structural ceiling, or whether Boston Scientific is a broad, cash-generative device portfolio whose other three-quarters still compound at about 6%, currently obscured by a self-inflicted air pocket in the two franchises that used to do the heavy lifting. The answer decides whether today's multiple is an opportunity to own a durable compounder or a fair price for a company that has quietly become slower.